<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03106701</url>
  </required_header>
  <id_info>
    <org_study_id>IRCCSDonato</org_study_id>
    <nct_id>NCT03106701</nct_id>
  </id_info>
  <brief_title>Epicardial Ablation in Brugada Syndrome. An Extension Study of 500 BrS.Patients</brief_title>
  <official_title>Epicardial Ablation in 500 Consecutive Brugada Syndrome Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Donato</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Policlinico S. Donato</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study represents an extension of a previous study (NCT02641431) on the acute and
      long-term benefit of epicardial ablation on elimination of both BrS-ECG pattern and VT/VF
      inducibility in 500 consecutive BrS patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to previous protocol (NCT02641431), 300 additional consecutive selected patients
      having an ICD implantation will be enrolled up to a total of 500 BrS patients.
      Echocardiography with cardiac deformation analysis, three-dimensional color-coded voltage,
      activation and duration electroanatomical maps before and after ajmaline (1mg/kg in 5
      minutes) wiil determine the site and the size of the arrhythmogenic substrate as
      characterized by abnormally prolonged fragmented ventricular potentials and potential wall
      motion abnormalities. Primary endpoint will be identification and elimination of this
      electrophysiological substrate by RF applications leading to ECG pattern normalization and
      VT/VF non-inducibility before and after ajmaline. Patients will be followed up to 10 years
      after ablation by sequential 12-lead ECG and Holter recording, Echocardiography, ICD
      interrogation, VT/VF inducibility patterns before and after ajmaline test.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2028</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Type 1 BrS-ECG pattern elimination by epicardial ablation before and after ajmaline test.</measure>
    <time_frame>1 day after ablation</time_frame>
    <description>Normalization of ECG pattern after elimination by radio-frequency ablation of all abnormal epicardial potentials</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VT/VF inducibility</measure>
    <time_frame>immediately after mapping and ablation</time_frame>
    <description>Programmed stimulation was achieved at twice the diastolic threshold and randomly performed at RV apex and RV outflow tract using up to 3 drive cycle lengths (from 600 to 350ms) and up to three extrastimuli (S2-S4) delivered from the apex and outflow tract of the right ventricle.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Absence of VT/VF</measure>
    <time_frame>1,3,6,12,18,24,36,48,60,72,84,96,108,120 months after ablation</time_frame>
    <description>Absence of VT/VF by ICD interrogation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absence of Br Pattern and RV mechanical abnormalities using echo and cardiac deformation analysis before and after ajmaline test</measure>
    <time_frame>3 months</time_frame>
    <description>Abolition of typical BrS-ECG pattern and RV mechanical abnormalities before and after ajmaline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of VA episodes at EP study</measure>
    <time_frame>3 months</time_frame>
    <description>Non-inducibility of VT/VT at programmed electrophysiological study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Br Pattern at ajmaline test</measure>
    <time_frame>6 months</time_frame>
    <description>Normalization of 12-lead ECG recording and echo parameters at baseline and after ajmaline test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of VA episodes</measure>
    <time_frame>6 months</time_frame>
    <description>ICD interrogation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of VA episodes</measure>
    <time_frame>12 months</time_frame>
    <description>ICD interrogation and ajmaline test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Br Pattern at ajmaline test</measure>
    <time_frame>12 months</time_frame>
    <description>Normalization of 12-lead ECG recording and echo parameters at baseline and after ajmaline test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Br Pattern at ajmaline test</measure>
    <time_frame>18 months</time_frame>
    <description>Normalization of 12-lead ECG recording at baseline and after ajmaline test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of VA episodes</measure>
    <time_frame>24 months</time_frame>
    <description>ICD interrogation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Br ECG pattern after ajmaline test</measure>
    <time_frame>24 months</time_frame>
    <description>Normalization of 12-lead ECG recording at baseline and after ajmaline test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of VA episodes at EP study</measure>
    <time_frame>36 months</time_frame>
    <description>ICD interrogation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Br Pattern at ajmaline test</measure>
    <time_frame>36 months</time_frame>
    <description>Normalization of 12-lead ECG recording at baseline and after ajmaline test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Br Pattern at ajmaline test</measure>
    <time_frame>48 months</time_frame>
    <description>Normalization of 12-lead ECG recording at baseline and after ajmaline test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of VA episodes at EP study</measure>
    <time_frame>48 months up to 120 months</time_frame>
    <description>ICD interrogation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>ECG Brugada Pattern</condition>
  <arm_group>
    <arm_group_label>Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiofrequency epicardial ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ablation</intervention_name>
    <description>Epicardial Radiofrequency ablation</description>
    <arm_group_label>Ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic BrS patients, ICD implantation, spontaneous or ajmaline-induced type 1 Br
             pattern.

        Exclusion Criteria:

          -  Age &lt; 18 years, prior epicardial ablation, pregnancy, co-morbidities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo Pappone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Policlinico San Donato, Milan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlo Pappone, MD</last_name>
    <phone>+39 02 52774260</phone>
    <email>carlo.pappone@af-ablation.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS Policlinico S. Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <state>Milano</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Pappone, MD, PhD</last_name>
      <phone>00390252774260</phone>
      <email>carlo.pappone@af-ablation.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2017</study_first_submitted>
  <study_first_submitted_qc>April 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2017</study_first_posted>
  <last_update_submitted>March 24, 2018</last_update_submitted>
  <last_update_submitted_qc>March 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Donato</investigator_affiliation>
    <investigator_full_name>Carlo Pappone</investigator_full_name>
    <investigator_title>Department Director, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brugada Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

